摘要
目的探讨苏盂鲁司特钠联合布地奈德气雾剂对咳嗽变异型哮喘(CVA)的临床治疗作用。方法 81例符合咳嗽变异性哮喘诊断标准的患者随机分为观察组42例,给予布地奈德气雾剂吸入和盂鲁司特钠口服。对照组39例,给予布地奈德气雾剂吸入。观察治疗前、治疗4周后血清总Ig E、外周血嗜酸性粒细胞计数(EOS)、肺活量(FVC)、最大呼气峰流速(PEF)的变化。结果治疗前两组患者IgE、EOS、FVC、PEF比较,差异无统计学意义(P>0.05)。治疗4周后,观察组IgE、EOS比对照组明显下降(P<0.05);FVC、PEF明显提高(P<0.05)。结论盂鲁司特钠联合布地奈德气雾剂吸入治疗咳嗽变异型哮喘疗效显著、不良反应较少,明显改善哮喘、咳嗽等临床症状。
Objective To observe the clinical efficacy of montelukast combined with budesonide aerosol in the treatment of patients with cough variant asthma. Methods 81 patients with CVA were randomly divided into the study group （42 cases）, which were given montelukast combined with budesonide aerosol inhalation, and the control group （39 cases）, which were only given budesonide aerosol inhalation. Their clinical efficacy, IgE, EOS, FVC and PEF were recorded and analyzed before and 4 weeks after the treatment. Results There was no significant difference in IgE, EOS, FVC and PEF between the two groups before the treatment （ P 〉 0. 05 ）. The expression of IgE and EOS decreased more significantly in the study group than in the control group 4 weeks after the treatment （P 〈 0. 05 ）, and the value of FVC and PEF increased more significantly in the study group than in the control group （ P 〈 0.05）. Conclusion Montelukast sodium combined with budesonide inhalation can greatly improve the clinical symptoms, such as asthma and cough, and there is less adverse reaction in the treatment of patients with CVA.
出处
《临床肺科杂志》
2015年第1期71-73,共3页
Journal of Clinical Pulmonary Medicine
